Proliferation inhibition effect of combination treatments
of ixazomib and chemotherapy agents
Next, we assessed whether the combination of ixazomib and commonly used
chemotherapy agents (cisplatin and fluorouracil) exhibits additive or
synergistic proliferation inhibition of ESCC cells. We applied a
universal reference experimental scheme (isobologram analysis) for
evaluating the effects of possible synergistic
interaction(Ooko et al. , 2017).
The ESCC cell lines were treated with varying concentrations of ixazomib
at indicated concentrations of cisplatin and fluorouracil for 24 h. In
Kyse150 and Kyse510 cells, the IC50-values of ixazomib
in combination with cisplatin were reduced by less than the
IC50 of ixazomib alone. However, we observed no similar
synergistic effects between ixazomib and fluorouracil in ESCC cells
(Figure 6A, B). This phenomenon suggests that the combination of
ixazomib and cisplatin has therapeutic potential in the treatment of
ESCC.